{"id":"W4396921377","doi":"10.1016/j.annonc.2024.04.001","title":"IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Chugai Pharmaceutical; Daiichi Sankyo Europe; Gilead Sciences; Servier; Seagen; Genentech; Veracyte; Jazz Pharmaceuticals; Ipsen; Queen Mary University of London; Clovis Oncology; Eisai; Natera; Baxalta; Les Laboratories Pierre Fabre; F. Hoffmann-La Roche; Amgen; Breast Cancer Research Foundation; Ariad Pharmaceuticals; Bayer HealthCare; Sanofi; Stryker; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Atezolizumab; Triple-negative breast cancer; Oncology; Metastatic breast cancer; Internal medicine; Chemotherapy; Double blind; Breast cancer; Cancer; Immunotherapy; Placebo; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001665211,0.00174147,0.002189474,0.0003422931,0.000427305,0.001006791,0.001021471,0.001972848,0.01165914],"category_scores_gemma":[0.001555096,0.0007637278,0.001727759,0.0003312003,0.001270379,0.0009350966,0.0005060857,0.003266783,0.001505201],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008484449,"about_ca_system_score_gemma":0.00151535,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007891478,"about_ca_topic_score_gemma":0.002684924,"domain_scores_codex":[0.9995083,0.0002461517,0.00002436739,0.00009983963,0.00003737671,0.00008395778],"domain_scores_gemma":[0.9993207,0.0001303485,0.0001490825,0.00007154788,0.00005636171,0.0002719843],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.968684,0.007037281,0.0004251639,0.0008838499,0.0006091825,0.00003287067,0.00004162794,0.0003013365,0.00397606,0.0002624369,0.002702583,0.01504363],"study_design_scores_gemma":[0.9646997,0.03276657,0.000645007,0.00003498852,0.0001320406,0.00002441546,0.000007234846,0.0002001412,0.0002767623,0.0001340016,0.001070165,0.000009034316],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9393926,0.008056457,0.001905,0.001978791,0.00208327,0.02824015,0.00667439,0.0005362422,0.01113311],"genre_scores_gemma":[0.9465062,0.003312529,0.003640409,0.003496696,0.0007550645,0.02226554,0.005501933,0.00008849455,0.01443314],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01165914,"threshold_uncertainty_score":0.03900373,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09997999724582605,"score_gpt":0.4500273928235163,"score_spread":0.3500473955776902,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}